Low to Moderate Load Power Training as an Exercise Intervention for Men With Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy.
Condition: Prostatic Neoplasms
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT07572760
Sponsor: University of Alicante
Eligibility:
- Age: minimum 50 Years maximum N/A
- Gender: Male
Inclusion Criteria:
- Histopathologically confirmed diagnosis of prostate adenocarcinoma. • Metastatic hormone-sensitive prostate cancer (mHSPC), defined as:
- Presence of metastases at initial diagnosis (synchronous mHSPC), or
- Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC).
- Evidence of progression to castration-resistant prostate cancer (CRPC).
- Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment.
- Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates.
- Presence of metastatic involvement limited to bone and/or lymph nodes.
- Functionally independent in activities of daily living.
Exclusion Criteria:
- Evidence of visceral metastatic disease.
- Current or prior treatment with a triplet regimen that includes chemotherapy.
- History of pathological fracture.
View trial on ClinicalTrials.gov